DeciBio的封面图片
DeciBio

DeciBio

商务咨询服务

Los Angeles,CA 16,223 位关注者

Precision Medicine Strategy Consulting

关于我们

DeciBio Consulting is a boutique strategy consulting firm focusing on the life science industry. DeciBio's mission is to provide strategic insights that accelerate innovation in precision medicine. Headquartered in Los Angeles, CA, DeciBio serves clients and customers across the globe, ranging from incubator-stage startups to Fortune 500 life science corporations. DeciBio addresses business solutions that range from market landscape analyses to full commercial strategies, including organic and inorganic growth opportunities (commercial due diligences). DeciBio’s work is typically supported by a mix of primary and secondary research leveraging Dexter, its in-house expert network, and DeciBio Analytics’ proprietary data intelligence products. DeciBio’s Analytics division offers numerous data products to support strategic insights, including in clinical diagnostics (the DxBooks), oncology biomarkers, liquid biopsy, NGS, spatial biology, omics market segmentation (Market Reports), the entire life sciences industry (BioTrack), and more. Internal teams such as the Culture Committee, Women* in Consulting, and Queers in Consulting enrich the employee experience. DeciBio’s Social Impact board and the DeciBio Impact Lab work collaboratively across divisions and externally to uproot discrimination and increase access to precision medicine. DeciBio Consulting, LLC recently launched DeciBio Ventures. This venture capital and creation firm invests in and supports ground-breaking companies in the precision medicine space.

网站
https://www.decibio.com
所属行业
商务咨询服务
规模
11-50 人
总部
Los Angeles,CA
类型
私人持股
创立
2009
领域
Market Research Reports、Corporate Strategy、In Vitro Diagnostics、Corporate and Investor Due Diligence、Molecular Diagnostics (MDx)、Next Generation Sequencing (NGS)、Life Science Research Tools、Companion Diagnostics (CDx)、Precision Medicine、Market Intelligence、Business Development、Go-to-Market Strategy和Opportunity Assessment

地点

  • 主要

    10203 Santa Monica Blvd

    #400

    US,CA,Los Angeles,90067

    获取路线

DeciBio员工

动态

  • 查看DeciBio的组织主页

    16,223 位关注者

    We're excited to kick off the new year with the inaugural Women of Precision Medicine: 25 Perspectives for 2025! This list features 25 exceptional women making an impact as leaders in precision medicine. From women’s health to cancer detection, digital pathology, AI, and beyond, their perspectives address key themes like diagnostic accessibility, equity in genomics, and the promise of multi-omics, emphasizing the transformative contributions of women across the field. This initiative was developed with the contributions of Tina Wang, Katie Maloney, Mané Mikayelyan, Megan Nacar, Kimmi Stacey, and Stephane Budel, whose efforts reflect a shared commitment to amplifying women’s voices and driving meaningful progress in precision medicine. Explore the publication and learn more about how to nominate a WOPM for future initiatives here: https://lnkd.in/gRZxwqFT #WOPM #Leadership #PrecisionMedicine

  • 查看DeciBio的组织主页

    16,223 位关注者

    Our #MeetTheTeam series continues! Meet our Vice President of Commercial, Megan Nacar. Megan brings over a decade of experience working on the commercial side of diagnostics, from pathology to clinical bioinformatics and next-generation sequencing. She plays a key role in shaping how we position DeciBio’s strategy work and market intelligence, ensuring our insights resonate with the industry and drive meaningful impact. From helping craft our thought leadership to fostering connections with key stakeholders, Megan helps bring our expertise to the forefront of precision medicine. But beyond her expertise, every member of our team brings a unique element of their personality to DeciBio. For Megan, that means sharing her passion for Formula 1—sparking discussions on strategy, precision, and maybe even a little friendly debate on race weekends. We believe the best teams thrive when they connect beyond the work they do, building on shared interests and diverse perspectives. ?? #CareersAtDeciBio

  • 查看DeciBio的组织主页

    16,223 位关注者

    At Precision Med TRI-CON 2025, David Cavanaugh took the stage to discuss one of the most pressing topics in diagnostics: how new regulations could reshape the landscape for LDTs. Key points included balancing innovation with regulatory compliance; potential effects on patient access to novel tests; and the impact on rare disease testing and oncology diagnostics. Missed the session or want to connect on this topic? Contact our team of experts! #TriCon2025 #LDTregulation #PrecisionMedicine

    • 该图片无替代文字
  • 查看DeciBio的组织主页

    16,223 位关注者

    Last week’s International Women’s Day Event was a powerful reminder of the importance of taking up space, sharing expertise, and shaping the conversations that define our industries. We’re proud to have women like Tina Wang and Megan Nacar at DeciBio who are making an impact in this space and beyond. Looking forward to continuing these important conversations! #InternationalWomensDay #WomenInLeadership #WomenInConsulting #PrecisionMedicine

    查看Tina Wang的档案

    Senior Project Leader at DeciBio | Precision Medicine | Strategy Consulting

    ???? ???????? ???? ???? ?????????????????????? ??????????????. ????'?? ?????? ?????? ?????? ????????, ????'?? ?????? ?????????? ??????. ???????????? ????????????????, ??????????'?? ?????? ???????? ???????????? ???? ?????? ?????????? ?????? ???????? ?????? ?????????????????? ?? ????????. ?????? ????????????????, "???????? ???? ?? ???????? ???? ????", ??????, "???????? ?????? ?? ????". ? These are just a few of my takeaways from our International Women's Day Event last Thursday. Reflecting on the event, I’m filled with gratitude for the inspiring discussions and incredible individuals who made it a success. ? ??A few of my key moments of appreciation: At the event, I had the opportunity to share a few words about DeciBio's commitment to women in leadership. I’m grateful for the firm’s continued support of initiatives like Women in Consulting, Women in Precision Medicine, and events like this that foster meaningful conversations. A huge thank you to our outstanding moderator and panelists for making our jobs easy, Stephen Abreu, Thane Kreiner, PhD, Mary Stutts, MHA., Shawnte Mitchell, and Sam Raha — your insights were invaluable, and I think I speak for everyone when I say we could have listened for another hour! And finally, the biggest thanks to my incredible co-organizers — Holly Uber, Cynthia Lee, Kenza Aboulhouda, and Megan Nacar. It was a privilege to work alongside such a talented and dedicated team. I'm looking forward to our next collaboration! #InternationalWomensDay #WomenInLeadership #WomenInConsulting #PrecisionMedicine Biopharma Leaders of Color (BLOC), Myriad Genetics, Healthcare Businesswomen’s Association

    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
  • 查看DeciBio的组织主页

    16,223 位关注者

    We are proud members of the The Alliance for Artificial Intelligence in Healthcare (AAIH) - thank you for sharing our IWD event from last Thursday! #IWD #WomensHistoryMonth

    The Alliance for Artificial Intelligence in Healthcare (AAIH)?is proud to highlight?DeciBio's #InternationalWomensDay event, hosted in partnership with?Myriad Genetics?last week in South San Francisco. This gathering brought together over?100 women?from across the life sciences and biotech industries for an evening dedicated to advancing women into decision-making roles. Among the speakers was?Megan Nacar,?AAIH member?and?Vice President of Commercial at DeciBio, who shared her personal journey into board service. She discussed her recent appointment as a?Board Advisor for Helio Genomics, a company leveraging?artificial intelligence and next-generation sequencing (NGS) to enhance early cancer detection, particularly for hepatocellular carcinoma (HCC)—one of the most prevalent and deadly forms of liver cancer. Megan’s story underscored a key theme of the night:?women belong at the table where industry-shaping decisions are made. The event provided a platform for women across all career stages to engage in meaningful discussions, build connections, and gain insight into how they can step into leadership and governance roles. The AAIH celebrates initiatives like this that align with our mission to foster diversity and inclusion in AI-driven healthcare innovation. When women’s voices are amplified in biotech and AI, we move closer to a future where technology and medicine serve?everyone?equitably. To learn more about DeciBio’s commitment to elevating women in leadership, visit DeciBio’s LinkedIn page, or follow along with the AAIH for updates on how we’re supporting diversity in AI-driven healthcare!

    • 该图片无替代文字
  • 查看DeciBio的组织主页

    16,223 位关注者

    March is a time to reflect on the contributions of women in science and healthcare, and what better way to do that than by revisiting our Women of Precision Medicine: 25 Perspectives for 2025 initiative? This list highlights 25 outstanding women who are advancing precision medicine and challenging the status quo. From expanding access to genomic testing and integrating AI into diagnostics to pioneering new approaches in cancer screening and women’s health, their insights offer a glimpse into the future of the field. As we celebrate Women's History Month, we invite you to explore their insights and nominate women who continue to drive impact in this space. Who are the women in precision medicine inspiring you? Read the full publication and submit nominations here: https://lnkd.in/gRZxwqFT #WomensHistoryMonth #WOPM #Leadership #PrecisionMedicine

    • 该图片无替代文字
  • 查看DeciBio的组织主页

    16,223 位关注者

    The DeciBio team is heading to the 32nd International Precision Med TRI-CON this week, and we’re bringing three expert speakers to the stage. If you're attending, don’t miss these insightful sessions: Speaking Sessions: ? Rebecca Burnham, PhD – Spatial Biology: Market Projections, Clinical Applications, and Future Trends (March 11, 1:25 PM) ? David Cavanaugh – The Future of Precision Medicine under New LDT Regulation (March 12, 2:35 PM) ? Luka Jelcic – AI-Driven Precision Medicine in Autoimmune Disorders (March 13, 11:30 AM) If you’ll be at Tri-Con, we’d love to connect. Reach out to schedule a meeting or join us for these discussions. See you there! #PrecisionMedicine #TriCon2025 #AIinHealthcare #SpatialBiology #LDTRegulation

    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
  • 查看DeciBio的组织主页

    16,223 位关注者

    ? February brought plenty of #LBx news, including numerous partnerships and collaborations, fundraising, and study data.?? ? Clinical and Regulatory? Natera announced that its Signatera test has received coverage from the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostics Services Program (MolDX) for NSCLC patients. ClearNote Health announced that their Avantect Pancreatic Cancer Test has been approved by the New York State Department of Health, making it available to clinicians in New York as a tool for pancreatic cancer early detection (EDx). Labcorp also launched its new Plasma Complete ctDNA CGP solution last month, designed to guide treatment decisions for advanced tumors.? ? Company Announcements & Product Launches? Foresight Diagnostics announced the expansion of their strategic collaboration with Allogene Therapeutics. Lynx Dx has launched ordering of its MyProstateScore 2.0 test’s at-home collection format. The test is ordered by physicians and is eligible for Medicare reimbursement. Meanwhile, Flatiron Health and Exact Sciences have announced a new collaboration aimed at generating clinical evidence for Exact’s MRD test, called Oncodetect, across a range of solid tumors. The first patient has already been enrolled.? ? Clinical Trials & Study Results? Researchers from the University of Washington and Fred Hutchinson Cancer Center have demonstrated the value of a prenatal cfDNA WGS assay for predicting preeclampsia. The test achieved 81% and 79% sensitivity in validation and external cohort analysis, respectively. A new pancreatic ductal adenocarcinoma (PDAC) assay was developed at Oregon Health & Science University. ? M&A | VC | Private Equity | Legal? PacBridge Capital Partners has backed AI health tech startup Avitia with $5M in seed funding. Avitia’s technology aims to enable cancer centers to perform NGS tests in-house, thereby improving affordability and accessibility. Syantra Inc. has received funding from Alberta Innovates to expand clinical studies of its Onco-ID: Breast screening test. The funding complements funding from the US DoD and will support a pilot study at the Mays Cancer Center at UT Health San Antonio. Oncocyte Corporation has raised $29.1M through concurrent offering to existing investors and private placements to fund its FDA IVD transplant assay program.? ? ? Read the newsletter for more:??https://lnkd.in/gGueNDjq ? Sign up to receive our Liquid Biopsy Newsletter in your email:?https://lnkd.in/gKQn7_zp ? The headlines have been handcrafted by Amal Thommil, Graham F., Nila Venkat, and Antony Awad?? ? #cancerdetection #earlydetection #precisionmedicine #productlaunches #cancermonitoring #liquidbiopsytesting?

  • DeciBio转发了

    查看Samuel P.的档案

    Life Sciences Strategy Consultant @ DeciBio | MBA, Biochemical Engineering

    What an experience! This past Friday, Team DeciBio - NYC took to the Bryant Park Cycle for Survival event, to join the fight against cancer. For those unfamiliar, Cycle for Survival is a global fundraising initiative led by Memorial Sloan Kettering Cancer Center (MSKCC) and Equinox to support rare cancer research. With MSK's extensive medical reach - over 2000 ongoing clinical trials tackling nearly 400 types of cancer - paired with Equinox's global infrastructure, this collaboration has been able to raise over $400 million since its inception in 2007. It's exciting to see MSK continue to form partnerships like this and the SOPHiA Genetics liquid biopsy initiative; both are helping to expand access to and adoption of life-changing cancer diagnostics and treatments. Big shoutout to my team on the ground Kimmi Stacey, Sylvia Illouz, and Alexander Nguyen, along with Megan Nacar for pushing us to participate. Looking forward to next year!

    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
  • 查看DeciBio的组织主页

    16,223 位关注者

    Happy International Women’s Day from DeciBio’s Women in Consulting Group! At DeciBio, our Women in Consulting (WIC) group is committed to fostering professional growth, accountability, and leadership within the firm and across the broader precision medicine industry. We meet regularly to set ambitious goals, champion each other’s success, and drive initiatives that create meaningful change. One of our key priorities last year was to see more women in leadership roles at the firm. Since then, we’ve proudly announced Katie Maloney as a Partner, a milestone that reflects our commitment to cultivating female leadership at DeciBio. But our efforts extend beyond our own walls—we’re also dedicated to amplifying the voices of women driving innovation across the industry. This commitment led to our latest initiative, Women of Precision Medicine, a curated list celebrating 25 women making a transformative impact in precision medicine. These leaders sit at the highest levels of their organizations, shaping the future of healthcare through groundbreaking work in genomics, diagnostics, bioinformatics, and beyond. You can read more about that initiative here: https://lnkd.in/gDbb2X7S We know that representation matters—not just in leadership, but in the voices that shape the industry’s trajectory. Today, we celebrate these remarkable women, our colleagues, and all those breaking barriers in STEM and healthcare. #InternationalWomensDay #WomenInLeadership #WomenInConsulting #WomenInPrecisionMedicine #DeciBio

    • 该图片无替代文字

关联主页

相似主页

查看职位